NasdaqHealth CareServices-Offices & Clinics of Doctors of MedicineCERRITOS, CA

Starling Oncology, Inc. STLN

Ask your AI

Estimated market cap $356.97M101.99M shares, shares as of Nov 3, 2026CIK 1799191

Insider trades, 12 mo

17 buys · 11 sells

$14.18M sold, open market

Congress trades, 24 mo

0 purchases, 5 sales

13F holders, Q3 2026

28.2% of shares · 35 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Starling Oncology, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 6, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Starling Oncology, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

28 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Recent insider trades

Jorey Chernett 10% owner	Nov 9 Form 4 ↗	Buy	+$176.3K 48,294 sh @ $3.65	-12.7%
Jorey Chernett 10% owner	Nov 6 Form 4 ↗	Sale	−$11.4M 2.85M sh @ $3.99	-5.9%
Brad Hively Director	Aug 21 Form 4 ↗	Sale 10b5-1 plan	−$1.9M 298,853 sh @ $6.51	-44.4%
Jorey Chernett 10% owner	Aug 14 Form 4 ↗	Buy	+$78.5K 12,000 sh @ $6.54	-42.9%
Jorey Chernett 10% owner	Jul 21 Form 4 ↗	Buy	+$94.9K 18,000 sh @ $5.27	-36.4%

All STLN insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

28.77M shares

85 funds report STLN. Values checked against market prices.

Funds own 39% of shares (Q2 2026)

120 funds hold the stock.

Q3 2026: 28% · 5,560 of ~8,900 funds reported so far

Q2 202535%
Q3 202535%
Q4 202539%
Q1 202639%
Q2 202639%
Q3 2026 (so far)28%

Q3 2026. 14 new, 35 added to, 21 trimmed, 49 exited since Q2 2026.

Top 13F holders
#
1	BlackRock, Inc. 13F ↗	5.33M	$33.7M	+12.2%
2	Vanguard Capital Management LLC 13F ↗	3.47M	$21.9M	+6.3%
3	Geode Capital Management, LLC 13F ↗	2.11M	$13.3M	+11.1%
4	Arrowstreet Capital, Limited Partnership 13F ↗	1.98M	$12.5M	+178.7%
5	State Street Corp 13F ↗	1.98M	$12.5M	+27.4%
6	Wexford Capital LP 13F ↗	1.71M	$10.8M	unchanged
7	Renaissance Technologies LLC 13F ↗	1.18M	$7.4M	-13.7%
8	FMR LLC 13F ↗	1.14M	$7.2M	+1358.8%
9	Vanguard Portfolio Management LLC 13F ↗	1.05M	$6.7M	+4.5%
10	Nuveen, LLC 13F ↗	962,202	$6.1M	-31.7%

Download CSV Every fund that holds STLN, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

5 in 24 mo

Disclosed in dollar ranges, up to 45 days after the trade.

Recent congressional trades

Richard Blumenthal D Senate · CT	Sale (partial) Spouse	$1,001 - $15,000	Sep 23 → Oct 26 ↗ 33d	-46.9%
Richard Blumenthal D Senate · CT	Sale (partial) Spouse	$15,001 - $50,000	Sep 22 → Oct 26 ↗ 34d	-47.9%
Richard Blumenthal D Senate · CT	Sale (partial) Spouse	$1,001 - $15,000	Sep 22 → Oct 26 ↗ 34d	-47.9%
Richard Blumenthal D Senate · CT	Sale (partial) Spouse	$15,001 - $50,000	Sep 18 → Oct 26 ↗ 38d	-48.8%
Richard Blumenthal D Senate · CT	Sale (partial) Spouse	$1,001 - $15,000	Sep 18 → Oct 26 ↗ 38d	-48.8%

All 5 trades →Free on every plan.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Starling Oncology, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Starling Oncology, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2021	1	—	252,439	$2.5M
Q4 2021	21	+20	21.12M	$199.9M
Q1 2022	29	+8	21.13M	$159.3M
Q2 2022	36	+7	21.90M	$110.9M
Q3 2022	39	+3	23.36M	$108.4M
Q4 2022	40	+1	23.53M	$39.2M
Q1 2023	39	-1	33.96M	$23.5M
Q2 2023	38	-1	13.92M	$7.7M
Q3 2023	36	-2	15.11M	$21.2M
Q4 2023	45	+9	18.47M	$38.3M
Q1 2024	47	+2	17.41M	$28.4M
Q2 2024	39	-8	18.70M	$8.8M
Q3 2024	34	-5	20.59M	$7.0M
Q4 2024	31	-3	14.71M	$4.6M
Q1 2025	43	+12	17.05M	$19.4M
Q2 2025	79	+36	32.26M	$66.1M
Q3 2025	108	+29	34.70M	$121.1M
Q4 2025	117	+9	38.48M	$137.1M
Q1 2026	116	-1	38.77M	$119.0M
Q2 2026	120	+4	40.09M	$217.6M
Q3 2026	85	-35	28.77M	$182.1M

Each point is a quarter-end, from Q3 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (68236X100). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes5 in 12 mo 8-K events5 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 6 in 12 mo Executive pay2 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record IPO history4 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Starling Oncology, Inc.
Address: 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA 90703
Phone: 562-735-3226
Fiscal year ends: Dec 31
Filer category: Accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: STLN (Nasdaq), DFPH (OTC), STLNW (Nasdaq)
Former names: Oncology Institute, Inc. (until 2026); DFP HEALTHCARE ACQUISITIONS CORP. (until 2021)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$3.50−$0.25 (−6.67%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $3.50 · High $6.94Nov 13, 2026

Aug 13, 2026Low $3.50 · High $7.05Nov 13, 2026

Nov 13, 2025Low $2.39 · High $7.05Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.